Interstitial lung disease
Conditions
Interventions
Sivelestat sodium application group:NA
Sivelestat sodium non-application group:NA
Sponsors
Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: (1) Patients aged =18 years old; (2) Patients met the diagnostic criteria for AE-ILD (see Appendix I for details); (3) Patients received sivelestat within 72 hours after onset; (4) Patients received conventional treatment in accordance with their conditions; (5) Patients could understand and abide by the requirements of the protocol and signed the informed consent voluntarily to participate in this study;
Exclusion criteria
Exclusion criteria: (1) Patients participating in other clinical studies; (2) Patients with serious lack of diagnosis and treatment data; (3) pregnant women, breastfeeding women or women who may be pregnant; (4) Combined with 3 or more severe organ dysfunction on the basis of the primary disease; (5) Patients diagnosed with neutropenia (absolute neutrophil count <2?109/L); (6) Patients who are receiving chemotherapeutics and other immunomodulatory drugs (such as recombinant human granulocyte colony-stimulating factor, thymus fasin, Xuebijin, ulinastatin, etc.); (7) patients who, as judged by the investigator, are not suitable for the study group (such as patients suffering from mental illness);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| dium: Oxygenation index improvement rate at day 5 and 7 day; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory index;Respiratory support mode and duration;Lung function;Arterial blood gas (partial pressure of oxygen, partial pressure of carbon dioxide);D-D dimer content or concentration;28 day mortality rate; | — |
Countries
China
Contacts
Public ContactBi Chen
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed